Probucol
Probucol
Contact Us

We are here to help in anything you need. Please use our online system or send an email to .

Probucol

Inquiry
Catalog Number PR23288495
CAS 23288-49-5
Structure
Description Probucol is a dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Synonyms Lorelco; Bisphenabid; Biphenabid; Bisbid; Lesterol; Lurselle
IUPAC Name 2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol
Molecular Weight 516.8
Molecular Formula C31H48O2S2
InChI FYPMFJGVHOHGLL-UHFFFAOYSA-N
InChI Key InChI=1S/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3
Documentation/Certification USDMF
Drug Categories Anticholesteremic Agents; Antioxidants; Benzene Derivatives; Biological Factors; Compounds used in a research, industrial, or household setting; Hypolipidemic Agents; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Moderate Risk QTc-Prolonging Agents; Phenols; Protective Agents; QTc Prolonging Agents
Drug Interactions Acrivastine-The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Probucol.
Adenosine-The risk or severity of QTc prolongation can be increased when Adenosine is combined with Probucol.
Ajmaline-The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Probucol.
Albuterol-The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Probucol.
Alfuzosin-The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Probucol.
Isomeric SMILES CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C
Type Small Molecule
Pharmacology

Indications

Probucol is primarily indicated for its role in lowering cholesterol levels, specifically targeting both low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol. It is utilized in clinical settings to manage and reduce cholesterol levels in patients who are at risk of cardiovascular diseases.

Pharmacodynamics

The pharmacodynamic action of probucol involves the enhancement of LDL breakdown, contributing significantly to its cholesterol-lowering effects. Additionally, it may exert an inhibitory effect on cholesterol synthesis while potentially delaying cholesterol absorption. As a potent antioxidant, probucol is also employed to mitigate vascular diseases that are instigated by free radicals within the body.

Absorption

When administered, the absorption of probucol from the gastrointestinal tract is generally limited and shows variability, with an average absorption rate of approximately 7%. This relatively low absorption rate necessitates consideration when determining appropriate dosing to achieve therapeutic efficacy.

Metabolism

Details regarding the metabolism of probucol are not readily available, which suggests that further research may be needed to fully elucidate its metabolic pathways. Nonetheless, understanding its pharmacokinetics remains crucial for optimizing its therapeutic application and managing potential interactions with other medications.

Mechanism of Action

Probucol effectively reduces serum cholesterol levels primarily by enhancing the catabolic rate of low-density lipoprotein (LDL), thereby facilitating cholesterol elimination from the body. In addition to its role in accelerating LDL breakdown, probucol may also inhibit early stages of cholesterol synthesis and decrease dietary cholesterol absorption. Recent findings indicate its potential in preventing LDL cholesterol oxidation and deposition in tissues, which plays a critical role in inhibiting the process of atherogenesis. Moreover, probucol appears to inhibit ABCA1-mediated cellular lipid efflux, contributing to its overall cholesterol-lowering effects.

It should be noted that our service is only used for research, not for clinical use.